IllumigynTM Raises $33M to Provide Women with Outstanding, Accessible, & Affordable Gynecological Care Worldwide
illumigyn , the world’s first remote gynecological imaging platform, has raised $33M following the closure of its latest investment round. This current investment round includes
Mirror Biologics Issued US Patent Covering Next Gen Therapeutic Vaccine Technology for Cancer & Infectious Disease Treatment
Mirror Biologics, Inc., received a US Patent No. 11,160,852 on the “Method of Vaccinating Using Allogeneic Cells,” covering methods for creating a next generation of
Oramed’s Oravax Oral COVID-19 Vaccine to Begin Phase 1 Clinical Trial
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed,com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced that its majority-owned
Alpha TAU Enrolls Its First Patient in Combination Trial of Alpha DaRT™ & Pembrolizumab (Keytruda)
Alpha Tau Medical Ltd., the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, has enrolled its first patient in the combination study of Alpha
Shaare Zedek Scientific Licenses Innovative Neuropsychiatric Cannabinoid Therapy to GCANRx
Shaare Zedek Scientific Ltd., the technology transfer arm of Jerusalem’s Shaare Zedek Medical Center, has entered into a licensing agreement with Greater Cannabis Company, Inc.
Ayana Pharma’s Generic, Cancer-killing Drug Got FDA Approval
Ayana Pharma’s Generic, Cancer-killing Drug Approved for Marketing by FDA The American Food and Drug Administration (FDA) has approved a groundbreaking, complex, generic drug indicated
Image Navigation is ushering in a New Era of Navigated and Robotic Dentistry!
Image Navigation is raising next round of funding for $8.5 million towards launch in US and European markets in 2022. Image Navigation, Ltd. Is preparing
Healables: A wearable that soothes and heals at home
Abigail Leichman from Israel21C visited Healables.ios in Jerusalem and met with Moshe Lebowitz, CEO of Healables.io (on the left, in the picture above, speaking to
Oramed Phase 2 Oral Insulin NASH Trial Reaches Over 50% Enrollment
Oramed Pharmaceuticals Inc., a Jerusalem-based clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, has enrolled over 50% of patients planned for
